Asset Details
Do you wish to reserve the book?
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis
Do you wish to request the book?
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis
2013
Overview
Background:
Epstein-Barr virus (EBV) infection is widely considered to be a risk factor for multiple sclerosis (MS). A previous meta-analysis estimated an odds ratio (OR) for MS in individuals seronegative for EBV of 0.06. Given the potential importance of this finding, we aimed to establish a more precise OR for adult and paediatric onset MS in EBV seronegative individuals.
Methods:
PubMed and EMBASE searches were undertaken to identify studies investigating the association between MS and EBV. Twenty-two adult and three paediatric studies were included. ORs were calculated using a fixed effects model. A sub-group analysis based on the method of EBV detection was performed.
Results:
The OR for developing adult MS in EBV seronegatives was 0.18 (95% confidence interval (CI) 0.13–0.26)) and for paediatric MS was 0.18 (95% CI 0.11–0.30). Sub-group analysis on EBV detection method showed that studies which used immunofluoresence generated an OR=0.07 (95% CI 0.03–0.16); for those that used enzyme-linked immunosorbent assay (ELISA) OR=0.33 (95% CI 0.22–0.50) and for studies which used ELISA and immunofluoresence OR=0.00 (95% CI 0–0.43).
Conclusion:
The sensitivity and specificity of the assay used to measure EBV antibody titres have an influence on the association between MS and EBV. Looking at studies where two independent methods are used and therefore are likely to be the most robust, EBV appears to be present in 100% of MS patients. This has implications for future studies of EBV in MS. MS patients without EBV infection, if they truly exist, should be studied in more detail.
Publisher
SAGE Publications,Sage Publications,Sage Publications Ltd
Subject
/ Adult
/ Biological and medical sciences
/ Data Interpretation, Statistical
/ Enzyme-Linked Immunosorbent Assay
/ Epstein-Barr Virus Infections - complications
/ Epstein-Barr Virus Infections - epidemiology
/ Female
/ Fluorescent Antibody Technique
/ Humans
/ Male
/ Multiple Sclerosis - epidemiology
/ Multiple Sclerosis - etiology
/ Risk
